1
|
Garnier Y, Claude L, Hermand P, Sachou E, Claes A, Desplan K, Chahim B, Roger PM, Martino F, Colin Y, Le Van Kim C, Baccini V, Romana M. Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine-dependent manner. Br J Haematol 2021; 196:1159-1169. [PMID: 34962643 DOI: 10.1111/bjh.18019] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Accepted: 12/13/2021] [Indexed: 12/15/2022]
Abstract
COVID-19 urges scientists to better describe its pathophysiology to find new therapeutic approaches. While risk factors such as ageing, obesity and diabetes mellitus suggest a central role of endothelial cells (ECs), autopsies revealed clots in the pulmonary microvasculature, which are rich in neutrophils and DNA traps produced by these cells and called NETs. Moreover, submicron extracellular vesicles called microparticles (MPs), are described in several diseases as involved in pro-inflammatory pathways. Therefore, we analyzed 3 patient groups: one for which intubation was not necessary, an intubated group, and the last one after extubating. In the most severe group, the intubated group, platelet-derived MPs and endothelial cell-derived MPs exhibited increased concentration and size, when compared to uninfected controls. MPs of intubated COVID-19 patients triggered ECs death and overexpression of two adhesion molecules: P-selectin and VCAM-1. Strikingly, neutrophils adhesion and NET production were increased following incubation with these ECs. Importantly, we also showed that preincubation of these COVID-19 MPs with the phosphatidylserine capping endogenous protein annexin A5, abolished cytotoxicity, P-selectin and VCAM-1 induction, all like increases in neutrophil adhesion and NET release. Altogether our results unveil that MPs are a key actor in COVID-19 pathophysiology and point towards a potential therapeutic: annexin A5.
Collapse
Affiliation(s)
- Yohann Garnier
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| | - Livia Claude
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| | - Patricia Hermand
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,Institut National de la Transfusion Sanguine, 75015, Paris, France
| | - Evely Sachou
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| | - Aurélie Claes
- Institut Pasteur, 75015, Paris, France.,CNRS ERL9195, 75015, Paris, France.,INSERM U1201, 75015, Paris, France
| | - Kassandra Desplan
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| | - Bassel Chahim
- Service de post-urgences, CHU Pointe à Pitre-Abymes, Pointe à Pitre, Guadeloupe, France
| | - Pierre-Marie Roger
- Service d'infectiologie CHU Pointe à Pitre-Abymes, Pointe à Pitre, Guadeloupe, France
| | - Frédéric Martino
- Service de réanimation, CHU Pointe à Pitre-Abymes, Pointe à Pitre, Guadeloupe, France
| | - Yves Colin
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,Institut National de la Transfusion Sanguine, 75015, Paris, France
| | - Caroline Le Van Kim
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,Institut National de la Transfusion Sanguine, 75015, Paris, France
| | - Véronique Baccini
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| | - Marc Romana
- Université de Paris, UMR_S1134, BIGR, INSERM, F-75015, Paris, France.,Université des Antilles, UMR_S1134, BIGR, F- 97157, Pointe-à-Pitre, France.,Laboratoire d'Excellence GR-Ex, Paris, France.,CHU de Pointe-à-Pitre, 97110, Guadeloupe, France
| |
Collapse
|
3
|
Rybczynska AA, Boersma HH, de Jong S, Gietema JA, Noordzij W, Dierckx RAJO, Elsinga PH, van Waarde A. Avenues to molecular imaging of dying cells: Focus on cancer. Med Res Rev 2018. [PMID: 29528513 PMCID: PMC6220832 DOI: 10.1002/med.21495] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Successful treatment of cancer patients requires balancing of the dose, timing, and type of therapeutic regimen. Detection of increased cell death may serve as a predictor of the eventual therapeutic success. Imaging of cell death may thus lead to early identification of treatment responders and nonresponders, and to “patient‐tailored therapy.” Cell death in organs and tissues of the human body can be visualized, using positron emission tomography or single‐photon emission computed tomography, although unsolved problems remain concerning target selection, tracer pharmacokinetics, target‐to‐nontarget ratio, and spatial and temporal resolution of the scans. Phosphatidylserine exposure by dying cells has been the most extensively studied imaging target. However, visualization of this process with radiolabeled Annexin A5 has not become routine in the clinical setting. Classification of death modes is no longer based only on cell morphology but also on biochemistry, and apoptosis is no longer found to be the preponderant mechanism of cell death after antitumor therapy, as was earlier believed. These conceptual changes have affected radiochemical efforts. Novel probes targeting changes in membrane permeability, cytoplasmic pH, mitochondrial membrane potential, or caspase activation have recently been explored. In this review, we discuss molecular changes in tumors which can be targeted to visualize cell death and we propose promising biomarkers for future exploration.
Collapse
Affiliation(s)
- Anna A Rybczynska
- Molecular Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.,Department of Genetics, University of Groningen, Groningen, the Netherlands
| | - Hendrikus H Boersma
- Molecular Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.,Department of Clinical Pharmacy & Pharmacology, University of Groningen, Groningen, the Netherlands
| | - Steven de Jong
- Department of Medical Oncology, University of Groningen, Groningen, the Netherlands
| | - Jourik A Gietema
- Department of Medical Oncology, University of Groningen, Groningen, the Netherlands
| | - Walter Noordzij
- Molecular Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - Rudi A J O Dierckx
- Molecular Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.,Department of Nuclear Medicine, Ghent University, Ghent, Belgium
| | - Philip H Elsinga
- Molecular Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| | - Aren van Waarde
- Molecular Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
| |
Collapse
|
5
|
Vangestel C, Peeters M, Mees G, Oltenfreiter R, Boersma HH, Elsinga PH, Reutelingsperger C, Van Damme N, De Spiegeleer B, Van de Wiele C. In vivo imaging of apoptosis in oncology: an update. Mol Imaging 2011; 10:340-58. [PMID: 21521554 DOI: 10.2310/7290.2010.00058] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2010] [Accepted: 08/05/2010] [Indexed: 01/09/2023] Open
Abstract
In this review, data on noninvasive imaging of apoptosis in oncology are reviewed. Imaging data available are presented in order of occurrence in time of enzymatic and morphologic events occurring during apoptosis. Available studies suggest that various radiopharmaceutical probes bear great potential for apoptosis imaging by means of positron emission tomography and single-photon emission computed tomography (SPECT). However, for several of these probes, thorough toxicologic studies are required before they can be applied in clinical studies. Both preclinical and clinical studies support the notion that 99mTc-hydrazinonicotinamide-annexin A5 and SPECT allow for noninvasive, repetitive, quantitative apoptosis imaging and for assessing tumor response as early as 24 hours following treatment instigation. Bioluminescence imaging and near-infrared fluorescence imaging have shown great potential in small-animal imaging, but their usefulness for in vivo imaging in humans is limited to structures superficially located in the human body. Although preclinical tumor-based data using high-frequency-ultrasonography (US) are promising, whether or not US will become a routinely clinically useful tool in the assessment of therapy response in oncology remains to be proven. The potential of magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) for imaging late apoptotic processes is currently unclear. Neither 31P MRS nor 1H MRS signals seems to be a unique identifier for apoptosis. Although MRI-measured apparent diffusion coefficients are altered in response to therapies that induce apoptosis, they are also altered by nonapoptotic cell death, including necrosis and mitotic catastrophe. In the future, rapid progress in the field of apoptosis imaging in oncology is expected.
Collapse
|